Sars-CoV-2 circulating variants

This page describes circulating SARS-CoV-2 variants - Last update 15.03.2021


Table below in PDF:Table-Variants-SARS-CoV-2.pdf

L5F F S13I P26S R Q 52 R D80A T 9 5I I R102I (I) D138Y del Y 144 W152C F157L L R190S (S) D215G del L AL 242 - 244 D253G G V367F F K417N/T L452R R S477N (N) E484K K (K) N501Y/T Y T Y A570D D Q613H H D614G G G G A653V V H655Y Y Y Q677H H (H) P681H/R H (R) A701V V T716I I T859I D796Y /H Y F 888L L S982A A T1027I D1118 H H V1176F I1183V (V) G1219V V UKB.1.1.720I/501Y.V1 A222V N EU2B.1.?20A C R G G V EU1B.1.17720A G G CAL20CB.1.42920C B.1.525 B.1.526 A2819B/501T A2719B/501Y A.23.1 L18F F T20N F N S Y S N/T K Y G Y I F P.1 BrazilB.1.1.28.120J/501Y.V3 K G (I) (F) P.2 BrazilB.1.1.28.220? NTD S1 S2 S1 S2 RBD HR2 HR1 Signal 13 319 685 686 541 815816 912 984 1213 1163 CleavageS1/S2 CleavageS2? Del I K G H H B.1.1.318 Del A G N K Y G V SAB.1.35120H/501Y.V2 (F) (Del) Del Del Del NTD RBD HR2 HR1 Signal Del HV 69-70 S13I I C R G B.1.427 I Neutralizing antibodiesbinding ACE2 receptor andNeutralizing antibodiesbinding Fusion activity;modulates tropism Fusion activity;modulates tropism B.1.375 Spike variants vs Wuhan-Hu1 (19A) Common name:PANGO name:Nextstrain name: ,
LineagesynonymsEmergenceSpike substitutionsOther substitutionsConsensus fastaPhenotypes
19AWuhan-Hu-1, nCoV China, Dec. 2019NoneNoneGenome
Spike protein
All proteins		Reference for variants
B.1.1.7
>PANGO
>BV-BRC		20I/501Y.V1,
VOC 202012/01		UK, September 2020 Del 69-70, Del 144, N501Y, A570D, D614G, P681H, T716I, S982A, D1118H orf1ab:T1001I, orf1ab:A1708D, orf1ab:I2230T, del:11288:9, del:21765:6, del:21991:3, Orf8:R52I, Orf8:Q27*, Orf8:Y73C, N:D3L, N:S235Fgenome
Spike protein
All proteins		Increased transmissibility: 36-75%. Potential increase in risk of hospitalization (40-64%) and risk of death (30-70%). No adverse effects on vaccine efficacy.y
B.1.351
>PANGO
>BV-BRC		20H/501Y.V2South Africa, Aug 2020 (L18F), D80A, D215G , (Del 242-244), K417N, E484K, N501Y, D614G, A701V E:P71L, N:T205I, orf1a:K1655Ngenome
Spike protein
All proteins		Increased transmissibility: approximately 50%. Potential increase in risk of death during hospitalization (20%). Impacts immune escape after infection and after vaccination.
P.1
>PANGO
>BV-BRC		B.1.1.28.1, 20J/501Y.V3Brazil, July 2020 L18F, T20N, P26S, D138Y, R190S, K417N/T, E484K, N501Y, D614G, H655Y, T1027I, V1176Forf1ab:S1188L, orf1ab:K1795Q, del:11288:9,
orf3a:G174C, orf8:E92K
N:P80R		genome
Spike protein
All proteins		Increased transmissibility: 40-120%. No impact reported on disease severity. Impacts immune escape after infection and after vaccination.
P.2
>PANGO		B.1.1.28.2Brasil, Oct. 2020E484K, D614G, (T859I), (V1176F)No impact on public health reported (April 2021).
B.1.1.318
>PANGO		Switzerland, Janv 2021T95I, DelY144, E484K, D614G, Q677H, D796H
B.1.375
>PANGO
>BV-BRC		USA, Sept 2020Del H69-V70
D614G		orf1ab:T1828A,
orf1b:E1264D,
orf3a: T151I,
M:I48V		genome
S Protein
All proteins		S gene target failure (SGTF)
B.1.427
>PANGO		California(CA)USA Sept. 2020S13I, W152C, L452R, D614Gorf1a:T265I, S3158T, orf1b:P314L, P976L, D1183Y,
orf3a:Q57H,
N:T205I		May display increased transmission and decreased neutralization by convalescent plasma and vaccines
B.1.429
>PANGO
>BV-BRC		CAL.20CCalifornia July 2020S13I, W152C, L452R, D614Gorf1a:T265I, I4205V, orf1b:P314L, D1183Y,
orf3a:Q57H,
N:T205I		genome
Spike protein
All proteins		May display increased transmission and decreased neutralization by convalescent plasma and vaccines
B.1.525
>PANGO		Worldwide Dec.2020 Q52R, E484K, D614G, Q677H, F888L orf1ab:L4715F, E:L21F, E:I82T, del:11288:9, del:21765:6, del:28278:3
B.1.526
>PANGO		USA Sept 2020L5F, T95I, D253G, (S477N), (E484K), D614G, A701V
B.1.177
>PANGO		20A.EU1Europe, Jul. 2020A222V, D614G
B1.?20A.EU2Europe; Jun. 2020S477N, D614GMay increase resistance to mAb
A.23.1
>PANGO		Uganda Oct.2020(R102I), F157L, V367F, Q613H, (P681R)nsp3: E95K, nsp6: M86I, L98F, ORF 8: L84S, E92K and ORF9 N: S202N, Q418H

Sources: Vipr variants of concern
PANGO lineages
Societe Francaise de Microbiologie, Variants
The Variant Gambit: COVID?s Next Move